Improving the EASIX' predictive power for NRM in adults undergoing allogeneic hematopoietic cell transplantation BONE MARROW TRANSPL
Structural Stabilization of Clinically Oriented Oligomeric Proteins During their Transit through Synthetic Secretory Amyloids ADV SCI
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study Haematologica
EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation BONE MARROW TRANSPL
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study BRIT J HAEMATOL
Cellular and clinical impact of protein phosphatase enzyme epigenetic silencing in multiple cancer tissues Hum Genomics
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Mol Cancer Ther
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options Ann Hematol
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment CL LYMPH MYELOM LEUK
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study CL LYMPH MYELOM LEUK